Literature DB >> 16369008

A recombinant aspartyl protease of Coccidioides posadasii induces protection against pulmonary coccidioidomycosis in mice.

Eric J Tarcha1, Venkatesha Basrur, Chiung-Yu Hung, Malcolm J Gardner, Garry T Cole.   

Abstract

Coccidioidomycosis is a respiratory disease of humans caused by the desert soil-borne fungal pathogens Coccidioides spp. Recurrent epidemics of this mycosis in the southwestern United States have contributed significantly to escalated health care costs. Clinical and experimental studies indicate that prior symptomatic coccidioidomycosis induces immunity against subsequent infection, and activation of T cells is essential for containment of the pathogen and its clearance from host tissue. Development of a human vaccine against coccidioidomycosis has focused on recombinant T-cell-reactive antigens which elicit a durable protective immune response against pulmonary infection in mice. In this study we fractionated a protective multicomponent parasitic cell wall extract in an attempt to identify T-cell antigens. Immunoblots of electrophoretic separations of this extract identified patient seroreactive proteins which were subsequently excised from two-dimensional polyacrylamide gel electrophoresis gels, trypsin digested, and sequenced by tandem mass spectrometry. The full-length gene which encodes a dominant protein in the immunoblot was identified using established methods of bioinformatics. The gene was cloned and expressed, and the recombinant protein was shown to stimulate immune T cells in vitro. The deduced protein was predicted to contain epitopes that bind to human major histocompatibility complex class II molecules using a TEPITOPE-based algorithm. Synthetic peptides corresponding to the predicted T-cell epitopes induced gamma interferon production by immune T lymphocytes. The T-cell-reactive antigen, which is homologous to secreted fungal aspartyl proteases, protected mice against pulmonary infection with Coccidioides posadasii. We argue that this immunoproteomic/bioinformatic approach to the identification of candidate vaccines against coccidioidomycosis is both efficient and productive.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16369008      PMCID: PMC1346669          DOI: 10.1128/IAI.74.1.516-527.2006

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  50 in total

Review 1.  Immunoreactivity of the fungal cell wall.

Authors:  J Pontón; M J Omaetxebarría; N Elguezabal; M Alvarez; M D Moragues
Journal:  Med Mycol       Date:  2001       Impact factor: 4.076

2.  A metalloproteinase of Coccidioides posadasii contributes to evasion of host detection.

Authors:  Chiung-Yu Hung; Kalpathi R Seshan; Jieh-Juen Yu; Ruth Schaller; Jianmin Xue; Venkatesha Basrur; Malcolm J Gardner; Garry T Cole
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

3.  Coccidioides immitis vaccine: potential of an alkali-soluble, water-soluble cell wall antigen.

Authors:  G Lecara; R A Cox; R B Simpson
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

4.  A simple method for displaying the hydropathic character of a protein.

Authors:  J Kyte; R F Doolittle
Journal:  J Mol Biol       Date:  1982-05-05       Impact factor: 5.469

5.  Immunization of mice against coccidioidomycosis with a subcellular vaccine.

Authors:  D Pappagianis; R Hector; H B Levine; M S Collins
Journal:  Infect Immun       Date:  1979-07       Impact factor: 3.441

6.  An epidemic of coccidioidomycosis in Arizona associated with climatic changes, 1998-2001.

Authors:  Benjamin J Park; Keith Sigel; Victorio Vaz; Ken Komatsu; Cheryl McRill; Maureen Phelan; Timothy Colman; Andrew C Comrie; David W Warnock; John N Galgiani; Rana A Hajjeh
Journal:  J Infect Dis       Date:  2005-04-20       Impact factor: 5.226

7.  DNA immunization using a secreted cell wall antigen Mp1p is protective against Penicillium marneffei infection.

Authors:  Lei-Po Wong; Patrick C Y Woo; Adrian Y Y Wu; Kwok-Yung Yuen
Journal:  Vaccine       Date:  2002-07-26       Impact factor: 3.641

8.  Protection against systemic candidiasis in mice immunized with secreted aspartic proteinase 2.

Authors:  Manuel Vilanova; Luzia Teixeira; Iris Caramalho; Egídio Torrado; Andreia Marques; Pedro Madureira; Adília Ribeiro; Paula Ferreira; Miguel Gama; Jocelyne Demengeot
Journal:  Immunology       Date:  2004-03       Impact factor: 7.397

9.  Proteomics-based identification of novel Candida albicans antigens for diagnosis of systemic candidiasis in patients with underlying hematological malignancies.

Authors:  Aida Pitarch; Joaquín Abian; Montserrat Carrascal; Miguel Sánchez; César Nombela; Concha Gil
Journal:  Proteomics       Date:  2004-10       Impact factor: 3.984

10.  Role of signal sequence in vaccine-induced protection against experimental coccidioidomycosis.

Authors:  Chengyong Jiang; D Mitchell Magee; F Douglas Ivey; Rebecca A Cox
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

View more
  30 in total

Review 1.  [Therapeutic or prophylactic antifungal vaccination: problems and solutions].

Authors:  S Boneberger; H C Korting
Journal:  Hautarzt       Date:  2008-10       Impact factor: 0.751

2.  Vaccines to prevent systemic mycoses: holy grails meet translational realities.

Authors:  John N Galgiani
Journal:  J Infect Dis       Date:  2008-04-01       Impact factor: 5.226

3.  Call for a California coccidioidomycosis consortium to face the top ten challenges posed by a recalcitrant regional disease.

Authors:  George R Thompson; David A Stevens; Karl V Clemons; Josh Fierer; Royce H Johnson; Jane Sykes; George Rutherford; Michael Peterson; John W Taylor; Vishnu Chaturvedi
Journal:  Mycopathologia       Date:  2014-10-16       Impact factor: 2.574

4.  Multivalent recombinant protein vaccine against coccidioidomycosis.

Authors:  Eric J Tarcha; Venkatesha Basrur; Chiung-Yu Hung; Malcolm J Gardner; Garry T Cole
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

Review 5.  Vaccine immunity against fungal infections.

Authors:  Som G Nanjappa; Bruce S Klein
Journal:  Curr Opin Immunol       Date:  2014-03-03       Impact factor: 7.486

6.  Evaluation of two homologous proline-rich proteins of Coccidioides posadasii as candidate vaccines against coccidioidomycosis.

Authors:  Roger A Herr; Chiung-Yu Hung; Garry T Cole
Journal:  Infect Immun       Date:  2007-09-17       Impact factor: 3.441

7.  Progress Toward a Human Vaccine Against Coccidioidomycosis.

Authors:  Garry T Cole; Brady J Hurtgen; Chiung-Yu Hung
Journal:  Curr Fungal Infect Rep       Date:  2012-12-01

8.  A 25-kDa serine peptidase with keratinolytic activity secreted by Coccidioides immitis.

Authors:  Bárbara Gabriela Brum Lopes; André Luis Souza Dos Santos; Cláudia de Carvalho Falci Bezerra; Bodo Wanke; Márcia Dos Santos Lazéra; Marília Martins Nishikawa; Ana Maria Mazotto; Vânia Monteiro Kussumi; Rosa Maria Tavares Haido; Alane Beatriz Vermelho
Journal:  Mycopathologia       Date:  2008-04-02       Impact factor: 2.574

9.  Preclinical identification of vaccine induced protective correlates in human leukocyte antigen expressing transgenic mice infected with Coccidioides posadasii.

Authors:  Brady J Hurtgen; Natalia Castro-Lopez; Maria Del Pilar Jiménez-Alzate; Garry T Cole; Chiung-Yu Hung
Journal:  Vaccine       Date:  2016-09-09       Impact factor: 3.641

10.  Construction and evaluation of a novel recombinant T cell epitope-based vaccine against Coccidioidomycosis.

Authors:  Brady J Hurtgen; Chiung-Yu Hung; Gary R Ostroff; Stuart M Levitz; Garry T Cole
Journal:  Infect Immun       Date:  2012-09-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.